Brief: Cipla's Manufacturing Facility In Goa Undergoes US FDA Inspection
17/04/2026 12:32
April 17 (Reuters) - Cipla Ltd CIPL.NS: CIPLA - USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN GOA, INDIA CIPLA - USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN GOA, INDIA CIPLA - USFDA CONDUCTS INSPECTION AT CIPLA GOA FACILITY FROM APRIL 6-17, 2026 CIPLA - RECEIVES TWO INSPECTIONAL OBSERVATIONS IN FORM 483 Source text: ID:nBSE5VLYW0 Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cipla
See all newsIndian pharma stocks up on report US taps drugmakers for critical cancer drug
India's Cipla jumps after Citi sees near-term positive triggers for earnings
Factbox: Global drugmakers invest billions to boost US presence
India raises price cap on cancer drugs to tackle shortage
Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated